Arcus Biosciences (RCUS) Stock Price, News & Analysis

Company Overview

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody. Additional pipeline assets explore dual checkpoint blockade and next-generation immune modulators. Arcus conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic institutions and global partners to advance its oncology portfolio.

Founded in 2015 and headquartered in Redwood City, California, Arcus completed its initial public offering on the New York Stock Exchange in June 2020 under the ticker RCUS. The company has since forged strategic alliances with leading biopharmaceutical firms to accelerate clinical development and broaden the potential application of its immuno-oncology therapeutics.

Arcus is led by President and Chief Executive Officer Terry Rosen, who co-founded the company and brings extensive experience in biotech leadership and oncology drug development. The senior management team combines expertise in translational medicine, clinical operations and commercial strategy to guide Arcus toward its goal of delivering new treatment options for patients with cancer.

Key Stats

• Today's Range: $25.25 to $26.70
• 50-Day Range: $18.76 to $26.69
• 52-Week Range: $7.06 to $28.72
• Volume: 1.15 million shs
• Average Volume: 1.26 million shs
• Market Capitalization: $3.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.44
• Consensus Rating: Moderate Buy

Arcus Biosciences Stock Analysis - MarketRank™

Arcus Biosciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 644th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Arcus Biosciences has a consensus price target of $32.44, representing about 24.4% upside from its current price of $26.09.

Amount of Analyst Coverage

Arcus Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcus Biosciences are expected to grow in the coming year, from ($3.73) to ($2.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcus Biosciences is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcus Biosciences is -7.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcus Biosciences has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.77% of the float of Arcus Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcus Biosciences has a short interest ratio ("days to cover") of 12.16, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcus Biosciences has recently increased by 12.13%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcus Biosciences does not currently pay a dividend.

Dividend Growth

Arcus Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 6 news articles for Arcus Biosciences this week, compared to 4 articles on an average week.

MarketBeat Follows

2 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcus Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of Arcus Biosciences is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RCUS Stock Analysis - Frequently Asked Questions

How have RCUS shares performed this year?

Arcus Biosciences' stock was trading at $23.90 at the beginning of 2026. Since then, RCUS stock has increased by 9.1% and is now trading at $26.0850.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.10. The firm had revenue of $17 million for the quarter, compared to analysts' expectations of $29.49 million. Arcus Biosciences had a negative net margin of 142.91% and a negative trailing twelve-month return on equity of 65.77%.
Read the conference call transcript.

When did Arcus Biosciences IPO?

Arcus Biosciences (RCUS) raised $112 million in an initial public offering on Thursday, March 15th 2018. The company issued 8,000,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Top institutional shareholders of Arcus Biosciences include Bank of New York Mellon Corp (0.41%), Principal Financial Group Inc. (0.33%), New York State Teachers Retirement System (0.07%) and Y Intercept Hong Kong Ltd (0.07%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Carolyn C Tang, Robert C Goeltz II, Richard Markus, Yasunori Kaneko and Alexander Azoy.
View institutional ownership trends.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Today: 5/05/2026
• Last Earnings: 5/05/2026
• Next Earnings (Estimated): 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:RCUS
• CIK: 1724521
• Web: www.arcusbio.com
• Phone: (510) 694-6200
• Fax: N/A
• Employees: 500
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Arcus Biosciences: $32.44
• High Price Target: $47.00
• Low Price Target: $20.00
• Potential Upside/Downside: +24.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$353 million
• Net Margins: -142.91%
• Pretax Margin: -142.91%
• Return on Equity: -65.77%
• Return on Assets: -32.51%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 4.36
• Quick Ratio: 4.36

Sales & Book Value

• Annual Sales: $247 million
• Price / Sales: 13.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.84 per share
• Price / Book: 4.47

Miscellaneous

• Outstanding Shares: 125,629,000
• Free Float: 113,569,000
• Market Cap: $3.28 billion
• Optionable: Optionable
• Beta: 0.87